Zavegepant
As of the edition of 20 October 2026, Zavegepant is a small molecule: marketed, first approved in 2023 (US); acts on CALCRL; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Zavzpret
- First approved
- 9 March 2023 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 15, 3 stopped early
- Disease areas
- Nervous system; Lungs and airways; Ear, nose and throat; Eye; Immune system; Infections
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCRL | Calcitonin gene-related peptide type 1 receptor | Q16602 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 4 | 2 | 1 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 5 | 4 | 0 | 1 |
| Phase 4 | 2 | 0 | 1 | 1 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator and Lead sponsor of trials | 2019 to now |